STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Bonetto, Andrea ^a   Aydogdu, Tufan ^b,d   Kunzevitzky, Noelia ^b   Guttridge, Denis C ^c   Khuri, Sawsan ^b   Koniaris, Leonidas G ^a,b   Zimmers, Teresa A ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEASOME; SERUM AMYLOID A; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; CYTOKINE; TRANSCRIPTOME;

ACUTE PHASE RESPONSE; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CACHEXIA; CONTROLLED STUDY; DISEASE SEVERITY; GENE EXPRESSION; MOLECULAR PATHOLOGY; MOUSE; MUSCLE ATROPHY; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; ANIMAL; BLOOD; COLON TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; LIVER; METABOLISM; PATHOLOGY; SKELETAL MUSCLE; TUMOR CELL LINE;

MUS;

ACUTE-PHASE REACTION; ANIMALS; CACHEXIA; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER; MICE; MUSCLE, SKELETAL; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTOME;

EID: 79960611800     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022538     Document Type: Article

References (83)

1. Tan BH, Fearon KC, (2008) Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care 11: 400-407.
2. Tisdale MJ, (2009) Mechanisms of cancer cachexia. Physiol Rev 89: 381-410.
3. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, et al. (2002) Induction of cachexia in mice by systemically administered myostatin. Science 296: 1486-1488.
4. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, et al. (2008) Cachexia: a new definition. Clin Nutr 27: 793-799.
5. Grosvenor M, Bulcavage L, Chlebowski RT, (1989) Symptoms potentially influencing weight loss in a cancer population. Correlations with primary site, nutritional status, and chemotherapy administration. Cancer 63: 330-334.
6. Morrison SD, (1976) Control of food intake in cancer cachexia: a challenge and a tool. Physiol Behav 17: 705-714.
7. Argiles JM, Busquets S, Lopez-Soriano FJ, (2003) Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care 6: 401-406.
8. Naka T, Nishimoto N, Kishimoto T, (2002) The paradigm of IL-6: from basic science to medicine. Arthritis Res 4 (Suppl 3): S233-242.
9. Ohe Y, Podack ER, Olsen KJ, Miyahara Y, Miura K, et al. (1993) Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shortened survival in syngeneic mice. Br J Cancer 67: 939-944.
10. Tsujinaka T, Ebisui C, Fujita J, Kishibuchi M, Morimoto T, et al. (1995) Muscle undergoes atrophy in association with increase of lysosomal cathepsin activity in interleukin-6 transgenic mouse. Biochem Biophys Res Commun 207: 168-174.
11. Glass DJ, Apel ED, Shah S, Bowen DC, DeChiara TM, et al. (1997) Kinase domain of the muscle-specific receptor tyrosine kinase (MuSK) is sufficient for phosphorylation but not clustering of acetylcholine receptors: required role for the MuSK ectodomain? Proc Natl Acad Sci U S A 94: 8848-8853.
12. Black K, Garrett IR, Mundy GR, (1991) Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology 128: 2657-2659.
13. Zimmers TA, McKillop IH, Pierce RH, Yoo JY, Koniaris LG, (2003) Massive liver growth in mice induced by systemic interleukin 6 administration. Hepatology 38: 326-334.
14. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, et al. (2001) Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 3: 1014-1019.
15. Strassmann G, Fong M, Kenney JS, Jacob CO, (1992) Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89: 1681-1684.
16. Soda K, Kawakami M, Kashii A, Miyata M, (1995) Manifestations of cancer cachexia induced by colon 26 adenocarcinoma are not fully ascribable to interleukin-6. Int J Cancer 62: 332-336.
17. Strassmann G, Fong M, Freter CE, Windsor S, D'Alessandro F, et al. (1993) Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J Clin Invest 92: 2152-2159.
18. Tamura S, Ouchi KF, Mori K, Endo M, Matsumoto T, et al. (1995) Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clin Cancer Res 1: 1353-1358.
19. Scott HR, McMillan DC, Crilly A, McArdle CS, Milroy R, (1996) The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br J Cancer 73: 1560-1562.
20. Fearon KC, McMillan DC, Preston T, Winstanley FP, Cruickshank AM, et al. (1991) Elevated circulating interleukin-6 is associated with an acute-phase response but reduced fixed hepatic protein synthesis in patients with cancer. Ann Surg 213: 26-31.
21. Libonati JR, Howell AK, Incanno NM, Pettee KK, Glassberg HL, (2001) Brief muscle hypoperfusion/hyperemia: an ergogenic aid? J Strength Cond Res 15: 362-366.
22. Kushner I, (1993) Regulation of the acute phase response by cytokines. Perspect Biol Med 36: 611-622.
23. Tisdale MJ, (2002) Cachexia in cancer patients. Nat Rev Cancer 2: 862-871.
24. Falconer JS, Fearon KC, Ross JA, Elton R, Wigmore SJ, et al. (1995) Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 75: 2077-2082.
25. Stephens NA, Skipworth RJ, Fearon KC, (2008) Cachexia, survival and the acute phase response. Curr Opin Support Palliat Care 2: 267-274.
26. Barber MD, Ross JA, Fearon KC, (1999) Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. Nutr Cancer 35: 106-110.
27. Guida M, Ravaioli A, Sileni VC, Romanini A, Labianca R, et al. (2003) Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial. J Transl Med 1: 13.
28. Pavey SJ, Hawson GA, Marsh NA, (2001) Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinolysis 12: 51-58.
29. Preston T, Slater C, McMillan DC, Falconer JS, Shenkin A, et al. (1998) Fibrinogen synthesis is elevated in fasting cancer patients with an acute phase response. J Nutr 128: 1355-1360.
30. Tanaka Y, Eda H, Tanaka T, Udagawa T, Ishikawa T, et al. (1990) Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res 50: 2290-2295.
31. Diffee GM, Kalfas K, Al-Majid S, McCarthy DO, (2002) Altered expression of skeletal muscle myosin isoforms in cancer cachexia. Am J Physiol Cell Physiol 283: C1376-1382.
32. Acharyya S, Guttridge DC, (2007) Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome. Clin Cancer Res 13: 1356-1361.
33. Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, et al. (2004) Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 114: 370-378.
34. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA, (2003) Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52: 2784-2789.
35. Jin X, Zimmers TA, Perez EA, Pierce RH, Zhang Z, et al. (2006) Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. Hepatology 43: 474-484.
36. Jin X, Zhang Z, Beer-Stolz D, Zimmers TA, Koniaris LG, (2007) Interleukin-6 inhibits oxidative injury and necrosis after extreme liver resection. Hepatology 46: 802-812.
37. Mietus-Snyder M, Friera A, Glass CK, Pitas RE, (1997) Regulation of scavenger receptor expression in smooth muscle cells by protein kinase C: a role for oxidative stress. Arterioscler Thromb Vasc Biol 17: 969-978.
38. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL, (2001) Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A 98: 14440-14445.
39. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, et al. (2004) Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. Faseb J 18: 39-51.
40. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, et al. (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294: 1704-1708.
41. Vallania F, Schiavone D, Dewilde S, Pupo E, Garbay S, et al. (2009) Genome-wide discovery of functional transcription factor binding sites by comparative genomics: the case of Stat3. Proc Natl Acad Sci U S A 106: 5117-5122.
42. Snyder M, Huang XY, Zhang JJ, (2008) Identification of novel direct Stat3 target genes for control of growth and differentiation. J Biol Chem 283: 3791-3798.
43. Bourillot PY, Aksoy I, Schreiber V, Wianny F, Schulz H, et al. (2009) Novel STAT3 target genes exert distinct roles in the inhibition of mesoderm and endoderm differentiation in cooperation with Nanog. Stem Cells 27: 1760-1771.
44. Oh YM, Kim JK, Choi Y, Choi S, Yoo JY, (2009) Prediction and experimental validation of novel STAT3 target genes in human cancer cells. PLoS One 4: e6911.
45. Dauer DJ, Ferraro B, Song L, Yu B, Mora L, et al. (2005) Stat3 regulates genes common to both wound healing and cancer. Oncogene 24: 3397-3408.
46. Chen X, Xu H, Yuan P, Fang F, Huss M, et al. (2008) Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell 133: 1106-1117.
47. Juan TS, Wilson DR, Wilde MD, Darlington GJ, (1993) Participation of the transcription factor C/EBP delta in the acute-phase regulation of the human gene for complement component C3. Proc Natl Acad Sci U S A 90: 2584-2588.
48. Desiderio S, Yoo JY, (2003) A genome-wide analysis of the acute-phase response and its regulation by Stat3beta. Ann N Y Acad Sci 987: 280-284.
49. Allen DL, Cleary AS, Hanson AM, Lindsay SF, Reed JM, (2010) CCAAT/Enhancer Binding Factor-Delta Expression is Increased in Fast Skeletal Muscle by Food Deprivation and Regulates Myostatin Transcription In Vitro. Am J Physiol Regul Integr Comp Physiol.
50. McPherron AC, Lawler AM, Lee SJ, (1997) Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387: 83-90.
51. Darnell JE Jr, Kerr IM, Stark GR, (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1421.
52. Ihle JN, (1995) Cytokine receptor signalling. Nature 377: 591-594.
53. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, et al. (1999) Stat3 as an oncogene. Cell 98: 295-303.
54. Soda K, Kawakami M, Kashii A, Miyata M, (1994) Characterization of mice bearing subclones of colon 26 adenocarcinoma disqualifies interleukin-6 as the sole inducer of cachexia. Jpn J Cancer Res 85: 1124-1130.
55. Fujimoto-Ouchi K, Tamura S, Mori K, Tanaka Y, Ishitsuka H, (1995) Establishment and characterization of cachexia-inducing and-non-inducing clones of murine colon 26 carcinoma. Int J Cancer 61: 522-528.
56. Strassmann G, Kambayashi T, (1995) Inhibition of experimental cancer cachexia by anti-cytokine and anti-cytokine-receptor therapy. Cytokines Mol Ther 1: 107-113.
57. Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, et al. (1996) Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest 97: 244-249.
58. Davis C, Glasson D, (2001) Ectopic bone formation following temporalis muscle transposition for facial paralysis. Plast Reconstr Surg 107: 1918-1919.
59. Crepaldi T, Bersani F, Scuoppo C, Accornero P, Prunotto C, et al. (2007) Conditional activation of MET in differentiated skeletal muscle induces atrophy. J Biol Chem 282: 6812-6822.
60. Willis MS, Ike C, Li L, Wang DZ, Glass DJ, et al. (2007) Muscle ring finger 1, but not muscle ring finger 2, regulates cardiac hypertrophy in vivo. Circ Res 100: 456-459.
61. Lee SJ, Reed LA, Davies MV, Girgenrath S, Goad ME, et al. (2005) Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci U S A 102: 18117-18122.
62. Glass DJ, (2005) A signaling role for dystrophin: inhibiting skeletal muscle atrophy pathways. Cancer Cell 8: 351-352.
63. Glass DJ, (2005) Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 37: 1974-1984.
64. Glass DJ, (2003) Molecular mechanisms modulating muscle mass. Trends Mol Med 9: 344-350.
65. Glass DJ, (2003) Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol 5: 87-90.
66. Lai KM, Gonzalez M, Poueymirou WT, Kline WO, Na E, et al. (2004) Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. Mol Cell Biol 24: 9295-9304.
67. Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, et al. (2004) IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119: 285-298.
68. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, et al. (2004) The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 14: 395-403.
69. Abe JI, Che W, Yoshizumi M, Huang Q, Glassman M, et al. (2001) Bcr in vascular smooth muscle cells involvement of Ras and Raf-1 activation by Bcr. Ann N Y Acad Sci 947: 341-343.
70. Vernooy JH, Reynaert N, Wolfs TG, Cloots RH, Haegens A, et al. (2005) Rapid pulmonary expression of acute-phase reactants after local lipopolysaccharide exposure in mice is followed by an interleukin-6 mediated systemic acute-phase response. Exp Lung Res 31: 855-871.
71. Mitterhuemer S, Petzl W, Krebs S, Mehne D, Klanner A,et al. Escherichia coli infection induces distinct local and systemic transcriptome responses in the mammary gland. BMC Genomics 11: 138.
72. Ventadour S, Attaix D, (2006) Mechanisms of skeletal muscle atrophy. Curr Opin Rheumatol 18: 631-635.
73. Alonzi T, Maritano D, Gorgoni B, Rizzuto G, Libert C, et al. (2001) Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver. Mol Cell Biol 21: 1621-1632.
74. Mirka GA, Glasscock NF, Stanfield PM, Wilson JR, (2000) An empirical approach to characterizing trunk muscle coactivation using simulation input modeling techniques. J Biomech 33: 1701-1704.
75. Klover PJ, Clementi AH, Mooney RA, (2005) Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146: 3417-3427.
76. Glass DJ, (2007) Two tales concerning skeletal muscle. J Clin Invest 117: 2388-2391.
77. Weil WM, Glassner PJ, Bosco JA, 3rd, (2007) High-altitude illness and muscle physiology. Bull NYU Hosp Jt Dis 65: 72-77.
78. Jeschke MG, Chinkes DL, Finnerty CC, Kulp G, Suman OE, et al. (2008) Pathophysiologic response to severe burn injury. Ann Surg 248: 387-401.
79. Jin X, Zimmers TA, Zhang Z, Peirce RH, Koniaris LG, (2009) Interleukin-6 Is an Important In Vivo Inhibitor of Intestinal Epithelial Cell Death in Mice. Gut.
80. Zimmers TA, Pierce RH, McKillop IH, Koniaris LG, (2003) Resolving the role of IL-6 in liver regeneration. Hepatology 38: 1590-1591 author reply 1591.
81. Zimmers TA, Jin X, Hsiao EC, McGrath SA, Esquela AF, et al. (2005) Growth Differentiation Factor-15/Macrophage Inhibitory Cytokine-1 Induction After Kidney And Lung Injury. Shock 23: 543-548.
82. Zimmers TA, Jin X, Hsiao EC, Perez EA, Pierce RH, et al. (2006) Growth differentiation factor-15: induction in liver injury through p53 and tumor necrosis factor-independent mechanisms. J Surg Res 130: 45-51.
83. Schmittgen TD, Livak KJ, (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108.